Search

Your search keyword '"Negrini, Massimo"' showing total 992 results
Start Over Author "Negrini, Massimo"
992 results on '"Negrini, Massimo"'

3. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma

Author

Bergamini, Christian, Leoni, Ilaria, Rizzardi, Nicola, Melli, Mattia, Galvani, Giuseppe, Coada, Camelia Alexandra, Giovannini, Catia, Monti, Elisa, Liparulo, Irene, Valenti, Francesca, Ferracin, Manuela, Ravaioli, Matteo, Cescon, Matteo, Vasuri, Francesco, Piscaglia, Fabio, Negrini, Massimo, Stefanelli, Claudio, Fato, Romana, Gramantieri, Laura, and Fornari, Francesca

Published
2023
Full Text
View/download PDF

4. Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study

Author

Ramassone, Alice, D’Argenio, Andrea, Veronese, Angelo, Basti, Alessio, Soliman, Shimaa Hassan AbdelAziz, Volinia, Stefano, Bassi, Cristian, Pagotto, Sara, Ferracin, Manuela, Lupini, Laura, Saccenti, Elena, Balatti, Veronica, Pepe, Felice, Rassenti, Laura Z, Innocenti, Idanna, Autore, Francesco, Marzetti, Laura, Mariani-Costantini, Renato, Kipps, Thomas J, Negrini, Massimo, Laurenti, Luca, and Visone, Rosa

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Cancer, Hematology, Clinical Research, Lymphoma, Aetiology, 2.1 Biological and endogenous factors, Biomarkers, Tumor, Chromosome Aberrations, Clonal Evolution, Disease Progression, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Longitudinal Studies, Mutation, Prognosis, Survival Rate, Chronic lymphocytic leukemia, Copy number variation, Nucleotide variation, Clonal evolution, Cardiorespiratory Medicine and Haematology, Oncology and Carcinogenesis, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We investigated whether the selection and expansion of CLL clone(s) precede an aggressive disease shift. We found that clonal evolution occurs in all CLL patients, irrespective of the clinical outcome, but is faster during disease progression. In particular, changes in the frequency of nucleotide variants (NVs) in specific CLL-related genes may represent an indicator of poor clinical outcome.

Published
2019

5. Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Author

Vannini, Ivan, Wise, Petra M, Challagundla, Kishore B, Plousiou, Meropi, Raffini, Mirco, Bandini, Erika, Fanini, Francesca, Paliaga, Giorgia, Crawford, Melissa, Ferracin, Manuela, Ivan, Cristina, Fabris, Linda, Davuluri, Ramana V, Guo, Zhiyi, Cortez, Maria Angelica, Zhang, Xinna, Chen, Lu, Zhang, Shuxing, Fernandez-Cymering, Cecilia, Han, Leng, Carloni, Silvia, Salvi, Samanta, Ling, Hui, Murtadha, Mariam, Neviani, Paolo, Gitlitz, Barbara J, Laird-Offringa, Ite A, Nana-Sinkam, Patrick, Negrini, Massimo, Liang, Han, Amadori, Dino, Cimmino, Amelia, Calin, George A, and Fabbri, Muller

Abstract

In the originally published version of this Article, the positions of the final two authors in the author list were inadvertently inverted during the production process. This error has now been corrected in both the PDF and HTML versions of the Article.

Published
2018

6. Contributors

Author

Akanksha, Samuel, primary, Allione, Alessandra, additional, Álvarez-Perez, Juan Carlos, additional, Andrades, Alvaro, additional, Arenas, Alberto M., additional, Baliñas-Gavira, Carlos, additional, Barth, Dominik A., additional, Bielowski, Anna, additional, Biswas, Roopa, additional, Boeri, Mattia, additional, Broseghini, Elisabetta, additional, Calin, George A., additional, Calura, Enrica, additional, Casalone, Elisabetta, additional, Constâncio, Vera, additional, Cosentino, Giulia, additional, Costa, Marina C., additional, Croce, Carlo M., additional, Cuadros, Marta, additional, Cutucache, Christine E., additional, Davidson, Ben, additional, Dika, Emi, additional, Dilmac, Sayra, additional, Dragomir, Mihnea P., additional, Drula, Rares, additional, Enguita, Francisco J., additional, Feng, Zhaohui, additional, Ferracin, Manuela, additional, Fornari, Francesca, additional, Fortunato, Orazio, additional, Gabriel, André F., additional, García, Daniel J., additional, Gramantieri, Laura, additional, Henrique, Rui, additional, Hu, Wenwei, additional, Iorio, Marilena V., additional, Jerónimo, Carmen, additional, Kamboj, Sakshi, additional, Kumar, Manoj, additional, Lawrie, Charles Henderson, additional, Leitão, Ana Lúcia, additional, Liu, Juan, additional, Lovat, Francesca, additional, Masatti, Laura, additional, Matullo, Giuseppe, additional, Medina, Pedro P., additional, Mohapatra, Swati, additional, Moisoiu, Vlad, additional, Negrini, Massimo, additional, Nguyen, Vu Hong Loan, additional, Anderson O’Brien, Jacob, additional, Ozpolat, Bulent, additional, Pardini, Barbara, additional, Patiño-Mercau, Juan Rodrigo, additional, Pazzaglia, Laura, additional, Peinado, Paola, additional, Pekarsky, Yuri, additional, Peng, Chun, additional, Petrescu, George E.D., additional, Pichler, Martin, additional, Plantamura, Ilaria, additional, Reich, Reuven, additional, Rodriguez, Maria Isabel, additional, Romualdi, Chiara, additional, Sanjuan-Hidalgo, Juan, additional, Scotlandi, Katia, additional, Shankaraiah, Ram C., additional, Slaby, Ondrej, additional, Solé, Carla, additional, Soni, Dharmendra Kumar, additional, Sozzi, Gabriella, additional, Thakur, Anamika, additional, Veronese, Angelo, additional, Visone, Rosa, additional, Vychytilova-Faltejskova, Petra, additional, and Zhang, Cen, additional

Published
2022
Full Text
View/download PDF

8. Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.

Author

Vannini, Ivan, Wise, Petra M, Challagundla, Kishore B, Plousiou, Meropi, Raffini, Mirco, Bandini, Erika, Fanini, Francesca, Paliaga, Giorgia, Crawford, Melissa, Ferracin, Manuela, Ivan, Cristina, Fabris, Linda, Davuluri, Ramana V, Guo, Zhiyi, Cortez, Maria Angelica, Zhang, Xinna, Chen, Lu, Zhang, Shuxing, Fernandez-Cymering, Cecilia, Han, Leng, Carloni, Silvia, Salvi, Samanta, Ling, Hui, Murtadha, Mariam, Neviani, Paolo, Gitlitz, Barbara J, Laird-Offringa, Ite A, Nana-Sinkam, Patrick, Negrini, Massimo, Liang, Han, Amadori, Dino, Cimmino, Amelia, Calin, George A, and Fabbri, Muller

Subjects
Lung, Cell Line, Tumor, Animals, Humans, Mice, Mice, Nude, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cyclins, MicroRNAs, Xenograft Model Antitumor Assays, Cell Proliferation, Down-Regulation, Gene Expression Regulation, Neoplastic, Up-Regulation, Base Sequence, Conserved Sequence, Genes, Tumor Suppressor, Female, RNA, Long Noncoding, Carcinogenesis, Cell Line, Tumor, Nude, Carcinoma, Non-Small-Cell Lung, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, RNA, Long Noncoding
Abstract

The transcribed ultraconserved regions (T-UCRs) encode long non-coding RNAs implicated in human carcinogenesis. Their mechanisms of action and the factors regulating their expression in cancers are poorly understood. Here we show that high expression of uc.339 correlates with lower survival in 210 non-small cell lung cancer (NSCLC) patients. We provide evidence from cell lines and primary samples that TP53 directly regulates uc.339. We find that transcribed uc.339 is upregulated in archival NSCLC samples, functioning as a decoy RNA for miR-339-3p, -663b-3p, and -95-5p. As a result, Cyclin E2, a direct target of all these microRNAs is upregulated, promoting cancer growth and migration. Finally, we find that modulation of uc.339 affects microRNA expression. However, overexpression or downregulation of these microRNAs causes no significant variations in uc.339 levels, suggesting a type of interaction for uc.339 that we call "entrapping". Our results support a key role for uc.339 in lung cancer.

Published
2017

10. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

Author

D'Abundo, Lucilla, Bassi, Cristian, Callegari, Elisa, Moshiri, Farzaneh, Guerriero, Paola, Michilli, Angelo, Mora, Fernanda, Gardini, Andrea Casadei, Sangiovanni, Angelo, Piscaglia, Fabio, Sabbioni, Silvia, Gramantieri, Laura, and Negrini, Massimo

Subjects
NUCLEOTIDE sequencing, LIVER cancer, HEPATOCELLULAR carcinoma, BLOOD serum analysis, LIVER diseases
Abstract

Hepatocellular carcinoma (HCC) is the most common liver cancer and is among the leading causes of cancer-related death worldwide. There is no reliable biomarker for the early diagnosis of HCC. Circulating microRNAs (miRNAs) have attracted attention as potential biomarkers of disease. By small-RNA next-generation sequencing, the analysis of serum miRNAs led to the identification of molecular signatures able to discriminate advanced HCC from early HCC (n = 246); advanced HCC from CIRRHOSIS (n = 299); advanced HCC from HEALTHY (n = 320); HEALTHY from early HCC (n = 343); and HEALTHY from CIRRHOSIS (n = 414). Cirrhotic patients and early HCC patients exhibited similar serum miRNA profiles, yet a small number of miRNAs (n = 57) were able to distinguish these two classes of patients. A second objective of the study was to identify serum miRNAs capable of predicting the response to therapy in patients with advanced HCC. All patients were treated with sorafenib as first-line therapy: 24 were nonresponsive and 24 responsive. Analysis of circulating miRNAs revealed a 54 miRNAs signature able to separate the two subgroups. This study suggested that circulating miRNAs could be useful biomarkers for monitoring patients with liver diseases ranging from cirrhosis to advanced HCC and possibly predicting susceptibility to first-line treatment based on sorafenib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.

Author

Cosi, Donato Michele, Fragale, Cristina, Magri, Chiara, Carnevale, Aldo, Ciancetta, Antonella, Guidoboni, Massimo, Negrini, Massimo, Bronte, Giuseppe, and Calabrò, Luana

Subjects
NON-small-cell lung carcinoma, ERLOTINIB, DASATINIB, OSIMERTINIB, PROTEIN-tyrosine kinase inhibitors, ARACHNOID cysts, CANCER patients, GENETIC mutation
Abstract

Third-generation tyrosine kinase inhibitors are the first-line gold standard in treating advanced non-small-cell lung cancer bearing common EGFR mutations, but data documenting clinical efficacy in uncommon mutations are currently limited. In this paper, we describe the case of a patient bearing uncommon compound EGFR mutations in exon 20, who experienced a near-complete response to third-line Osimertinib, with metabolic complete response of pulmonary, nodal and ostheolytic lesions. This radiological assessment corresponded to an ECOG PS improvement (from three to one) and a substantial clinical benefit for the patients. Out of two mutations, S768I was associated with poor response to third-generation TKI and V774M had unknown clinical significance, highlighting the complexity of the correct management of these kinds of mutations. We reviewed the literature to document the up-to-date preclinical and clinical data concerning third-generation tyrosine kinase inhibitors for the treatment of patients bearing uncommon EGFR mutations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

Author

Ferrajoli, Alessandra, Ivan, Cristina, Ciccone, Maria, Shimizu, Masayoshi, Kita, Yoshiaki, Ohtsuka, Masahisha, D'Abundo, Lucilla, Qiang, Jun, Lerner, Susan, Nouraee, Nazila, Rabe, Kari G, Rassenti, Laura Z, Van Roosbroeck, Katrien, Manning, John T, Yuan, Yuan, Zhang, Xinna, Shanafelt, Tait D, Wierda, William G, Sabbioni, Silvia, Tarrand, Jeffrey J, Estrov, Zeev, Radovich, Milan, Liang, Han, Negrini, Massimo, Kipps, Thomas J, Kay, Neil E, Keating, Michael, and Calin, George A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Genetics, Rare Diseases, Clinical Research, Cancer, Biotechnology, Hematology, Aetiology, 2.1 Biological and endogenous factors, Infection, Disease-Free Survival, Epstein-Barr Virus Nuclear Antigens, Herpesvirus 4, Human, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, MicroRNAs, RNA, Viral, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Viral Matrix Proteins, Viral Proteins, beta 2-Microglobulin, miRNAs, Epstein-Barr Virus, Chronic lymphocytic leukemia, BHRF1-1, Overall survival, Epstein–Barr Virus, Clinical Sciences, Public Health and Health Services, Clinical sciences, Epidemiology
Abstract

Although numerous studies highlighted the role of Epstein-Barr Virus (EBV) in B-cell transformation, the involvement of EBV proteins or genome in the development of the most frequent adult leukemia, chronic lymphocytic leukemia (CLL), has not yet been defined. We hypothesized that EBV microRNAs contribute to progression of CLL and demonstrated the presence of EBV miRNAs in B-cells, in paraffin-embedded bone marrow biopsies and in the plasma of patients with CLL by using three different methods (small RNA-sequencing, quantitative reverse transcription PCR [q-RT-PCR] and miRNAs in situ hybridization [miRNA-ISH]). We found that EBV miRNA BHRF1-1 expression levels were significantly higher in the plasma of patients with CLL compared with healthy individuals (p

Published
2015

14. Circulating CD8 Lymphocytes Predict Response to Atezolizumab‐Bevacizumab in Hepatocellular Carcinoma

Author

Gramantieri, Laura, primary, Suzzi, Fabrizia, additional, Bassi, Cristian, additional, D'Abundo, Lucilla, additional, Tovoli, Francesco, additional, Bruccoleri, Mariangela, additional, Marseglia, Mariarosaria, additional, Alimenti, Eleonora, additional, Fornari, Francesca, additional, Negrini, Massimo, additional, Iavarone, Massimo, additional, Piscaglia, Fabio, additional, and Giovannini, Catia, additional

Published
2023
Full Text
View/download PDF

19. miR-15 and miR-16 Induce Apoptosis by Targeting BCL2

Author

Cimmino, Amelia, Calin, George Adrian, Fabbri, Muller, Iorio, Marilena V., Ferracin, Manuela, Shimizu, Masayoshi, Wojcik, Sylwia E., Aqeilan, Rami I., Zupo, Simona, Dono, Mariella, Rassenti, Laura, Alder, Hansjuerg, Volinia, Stefano, Liu, Chang-gong, Kipps, Thomas J., Negrini, Massimo, and Croce, Carlo M.

Published
2005

26. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts

Author

Todeschini, Paola, Salviato, Elisa, Paracchini, Lara, Ferracin, Manuela, Petrillo, Marco, Zanotti, Laura, Tognon, Germana, Gambino, Angela, Calura, Enrica, Caratti, Giulia, Martini, Paolo, Beltrame, Luca, Maragoni, Lorenzo, Gallo, Daniela, Odicino, Franco E., Sartori, Enrico, Scambia, Giovanni, Negrini, Massimo, Ravaggi, Antonella, D'Incalci, Maurizio, Marchini, Sergio, Bignotti, Eliana, and Romualdi, Chiara

Published
2017
Full Text
View/download PDF

27. Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma.

Author

Gramantieri, Laura, Suzzi, Fabrizia, Bassi, Cristian, D'Abundo, Lucilla, Tovoli, Francesco, Bruccoleri, Mariangela, Marseglia, Mariarosaria, Alimenti, Eleonora, Fornari, Francesca, Negrini, Massimo, Iavarone, Massimo, Piscaglia, Fabio, and Giovannini, Catia

Subjects
LYMPHOCYTES, CD8 antigen, BIOMARKERS, RNA sequencing, HEPATOCELLULAR carcinoma
Abstract

Due to the lack of biomarkers predictive of response to atezolizumab–bevacizumab, the standard of care for advanced HCC, we analyzed baseline and early on‐treatment variation of peripheral lymphocyte populations of 37 prospective patients treated by atezolizumab–bevacizumab and in 15 prospective patients treated by sorafenib or lenvatinib (TKIs). RNAseq analysis followed by RT‐PCR validation on patients‐derived PBMC was also performed. At first imaging, re‐evaluation 13 patients receiving atezolizumab–bevacizumab, showed an objective response, 17 stable disease, while 7 were nonresponders. Baseline CD8+ and CD8+PD‐L1+ peripheral lymphocytes were lower in responders versus nonresponders (T‐test, p = 0.012 and 0.004, respectively). At 3 weeks, 28 of 30 responders displayed a rise of CD8+PD1+ lymphocytes with a positive mean fold change of 4.35 (±5.6 SD), whereas 6 of 7 nonresponders displayed a negative fold change of 0.89 (±0.84 SD). These changes were not observed in patients treated by TKIs. TRIM56, TRIM16, TRIM64, and Ki67 mRNAs were validated as upregulated in responders versus nonresponders after 3 weeks after treatment start, providing possible evidence of immune activation. Baseline CD8+ and CD8+PD‐L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab–bevacizumab providing noninvasive markers to complement clinical practice in the very early phases of treatment of HCC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. MicroRNA in Human Malignancies

Author

Negrini, Massimo, Calin, George A., Croce, Carlo M., Negrini, Massimo, Negrini, Massimo, Calin, George A., Croce, Carlo M., and Negrini, Massimo

Abstract

MicroRNA in Human Malignancies offers a deep overview of the role and translational significance of miRNAs in the development of cancer and other malignancies. The book establishes the foundations of the field by covering essential mechanisms and the translational potential of miRNAs in the field of oncology. Specific topics covered include invasion and metastasis, miRNAs and metabolism, and opportunities of miRNAs in therapeutics. Chapters on diseases include content on disease-related pathophysiology, as well as diagnostic, prognostic and predictive value. This book is an essential reference for students entering the field, as well as researchers and investigators. Provides fundamental and translational chapters that facilitate the acquisition of knowledge needed to design and perform innovative miRNA-related research studies Synthesizes current research, with a critical review on the field Offers in-depth research by leading experts in the field

Published
2022

31. Supplementary Material from MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma

Author

Gramantieri, Laura, primary, Pollutri, Daniela, primary, Gagliardi, Martina, primary, Giovannini, Catia, primary, Quarta, Santina, primary, Ferracin, Manuela, primary, Casadei-Gardini, Andrea, primary, Callegari, Elisa, primary, De Carolis, Sabrina, primary, Marinelli, Sara, primary, Benevento, Francesca, primary, Vasuri, Francesco, primary, Ravaioli, Matteo, primary, Cescon, Matteo, primary, Piscaglia, Fabio, primary, Negrini, Massimo, primary, Bolondi, Luigi, primary, and Fornari, Francesca, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

Author

Di Martino, Maria T., primary, Leone, Emanuela, primary, Amodio, Nicola, primary, Foresta, Umberto, primary, Lionetti, Marta, primary, Pitari, Maria R., primary, Cantafio, Maria E. Gallo, primary, Gullà, Annamaria, primary, Conforti, Francesco, primary, Morelli, Eugenio, primary, Tomaino, Vera, primary, Rossi, Marco, primary, Negrini, Massimo, primary, Ferrarini, Manlio, primary, Caraglia, Michele, primary, Shammas, Masood A., primary, Munshi, Nikhil C., primary, Anderson, Kenneth C., primary, Neri, Antonino, primary, Tagliaferri, Pierosandro, primary, and Tassone, Pierfrancesco, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 2 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

Author

Di Martino, Maria T., primary, Leone, Emanuela, primary, Amodio, Nicola, primary, Foresta, Umberto, primary, Lionetti, Marta, primary, Pitari, Maria R., primary, Cantafio, Maria E. Gallo, primary, Gullà, Annamaria, primary, Conforti, Francesco, primary, Morelli, Eugenio, primary, Tomaino, Vera, primary, Rossi, Marco, primary, Negrini, Massimo, primary, Ferrarini, Manlio, primary, Caraglia, Michele, primary, Shammas, Masood A., primary, Munshi, Nikhil C., primary, Anderson, Kenneth C., primary, Neri, Antonino, primary, Tagliaferri, Pierosandro, primary, and Tassone, Pierfrancesco, primary

Published
2023
Full Text
View/download PDF

34. Supplemetary Figure S4 from In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis

Author

Fornari, Francesca, primary, Pollutri, Daniela, primary, Patrizi, Clarissa, primary, La Bella, Tiziana, primary, Marinelli, Sara, primary, Casadei Gardini, Andrea, primary, Marisi, Giorgia, primary, Baron Toaldo, Marco, primary, Baglioni, Michele, primary, Salvatore, Veronica, primary, Callegari, Elisa, primary, Baldassarre, Maurizio, primary, Galassi, Marzia, primary, Giovannini, Catia, primary, Cescon, Matteo, primary, Ravaioli, Matteo, primary, Negrini, Massimo, primary, Bolondi, Luigi, primary, and Gramantieri, Laura, primary

Published
2023
Full Text
View/download PDF

35. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures from MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma

Author

Gramantieri, Laura, primary, Pollutri, Daniela, primary, Gagliardi, Martina, primary, Giovannini, Catia, primary, Quarta, Santina, primary, Ferracin, Manuela, primary, Casadei-Gardini, Andrea, primary, Callegari, Elisa, primary, De Carolis, Sabrina, primary, Marinelli, Sara, primary, Benevento, Francesca, primary, Vasuri, Francesco, primary, Ravaioli, Matteo, primary, Cescon, Matteo, primary, Piscaglia, Fabio, primary, Negrini, Massimo, primary, Bolondi, Luigi, primary, and Fornari, Francesca, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 6 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

Author

Di Martino, Maria T., primary, Leone, Emanuela, primary, Amodio, Nicola, primary, Foresta, Umberto, primary, Lionetti, Marta, primary, Pitari, Maria R., primary, Cantafio, Maria E. Gallo, primary, Gullà, Annamaria, primary, Conforti, Francesco, primary, Morelli, Eugenio, primary, Tomaino, Vera, primary, Rossi, Marco, primary, Negrini, Massimo, primary, Ferrarini, Manlio, primary, Caraglia, Michele, primary, Shammas, Masood A., primary, Munshi, Nikhil C., primary, Anderson, Kenneth C., primary, Neri, Antonino, primary, Tagliaferri, Pierosandro, primary, and Tassone, Pierfrancesco, primary

Published
2023
Full Text
View/download PDF

38. Data from MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma

Author

Gramantieri, Laura, primary, Pollutri, Daniela, primary, Gagliardi, Martina, primary, Giovannini, Catia, primary, Quarta, Santina, primary, Ferracin, Manuela, primary, Casadei-Gardini, Andrea, primary, Callegari, Elisa, primary, De Carolis, Sabrina, primary, Marinelli, Sara, primary, Benevento, Francesca, primary, Vasuri, Francesco, primary, Ravaioli, Matteo, primary, Cescon, Matteo, primary, Piscaglia, Fabio, primary, Negrini, Massimo, primary, Bolondi, Luigi, primary, and Fornari, Francesca, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Tables from MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma

Author

Gramantieri, Laura, primary, Pollutri, Daniela, primary, Gagliardi, Martina, primary, Giovannini, Catia, primary, Quarta, Santina, primary, Ferracin, Manuela, primary, Casadei-Gardini, Andrea, primary, Callegari, Elisa, primary, De Carolis, Sabrina, primary, Marinelli, Sara, primary, Benevento, Francesca, primary, Vasuri, Francesco, primary, Ravaioli, Matteo, primary, Cescon, Matteo, primary, Piscaglia, Fabio, primary, Negrini, Massimo, primary, Bolondi, Luigi, primary, and Fornari, Francesca, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Methods from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

Author

Di Martino, Maria T., primary, Leone, Emanuela, primary, Amodio, Nicola, primary, Foresta, Umberto, primary, Lionetti, Marta, primary, Pitari, Maria R., primary, Cantafio, Maria E. Gallo, primary, Gullà, Annamaria, primary, Conforti, Francesco, primary, Morelli, Eugenio, primary, Tomaino, Vera, primary, Rossi, Marco, primary, Negrini, Massimo, primary, Ferrarini, Manlio, primary, Caraglia, Michele, primary, Shammas, Masood A., primary, Munshi, Nikhil C., primary, Anderson, Kenneth C., primary, Neri, Antonino, primary, Tagliaferri, Pierosandro, primary, and Tassone, Pierfrancesco, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 5 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

Author

Di Martino, Maria T., primary, Leone, Emanuela, primary, Amodio, Nicola, primary, Foresta, Umberto, primary, Lionetti, Marta, primary, Pitari, Maria R., primary, Cantafio, Maria E. Gallo, primary, Gullà, Annamaria, primary, Conforti, Francesco, primary, Morelli, Eugenio, primary, Tomaino, Vera, primary, Rossi, Marco, primary, Negrini, Massimo, primary, Ferrarini, Manlio, primary, Caraglia, Michele, primary, Shammas, Masood A., primary, Munshi, Nikhil C., primary, Anderson, Kenneth C., primary, Neri, Antonino, primary, Tagliaferri, Pierosandro, primary, and Tassone, Pierfrancesco, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 2 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

44. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 1 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

Author

Di Martino, Maria T., primary, Leone, Emanuela, primary, Amodio, Nicola, primary, Foresta, Umberto, primary, Lionetti, Marta, primary, Pitari, Maria R., primary, Cantafio, Maria E. Gallo, primary, Gullà, Annamaria, primary, Conforti, Francesco, primary, Morelli, Eugenio, primary, Tomaino, Vera, primary, Rossi, Marco, primary, Negrini, Massimo, primary, Ferrarini, Manlio, primary, Caraglia, Michele, primary, Shammas, Masood A., primary, Munshi, Nikhil C., primary, Anderson, Kenneth C., primary, Neri, Antonino, primary, Tagliaferri, Pierosandro, primary, and Tassone, Pierfrancesco, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 1 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters

Author

Negrini, Massimo, primary, Cutrona, Giovanna, primary, Bassi, Cristian, primary, Fabris, Sonia, primary, Zagatti, Barbara, primary, Colombo, Monica, primary, Ferracin, Manuela, primary, D'Abundo, Lucilla, primary, Saccenti, Elena, primary, Matis, Serena, primary, Lionetti, Marta, primary, Agnelli, Luca, primary, Gentile, Massimo, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, Reverberi, Daniele, primary, Rigolin, Gianmatteo, primary, Calin, George A., primary, Sabbioni, Silvia, primary, Russo, Giandomenico, primary, Tassone, Pierfrancesco, primary, Morabito, Fortunato, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Tables 1 - 3 from Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features

Author

Morabito, Fortunato, primary, Mosca, Laura, primary, Cutrona, Giovanna, primary, Agnelli, Luca, primary, Tuana, Giacomo, primary, Ferracin, Manuela, primary, Zagatti, Barbara, primary, Lionetti, Marta, primary, Fabris, Sonia, primary, Maura, Francesco, primary, Matis, Serena, primary, Gentile, Massimo, primary, Vigna, Ernesto, primary, Colombo, Monica, primary, Massucco, Carlotta, primary, Recchia, Anna Grazia, primary, Bossio, Sabrina, primary, De Stefano, Laura, primary, Ilariucci, Fiorella, primary, Musolino, Caterina, primary, Molica, Stefano, primary, Di Raimondo, Francesco, primary, Cortelezzi, Agostino, primary, Tassone, Pierfrancesco, primary, Negrini, Massimo, primary, Monti, Sara, primary, Rossi, Davide, primary, Gaidano, Gianluca, primary, Ferrarini, Manlio, primary, and Neri, Antonino, primary

Published
2023
Full Text
View/download PDF

50. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results